22nd Century Group Inc (XXII)

1.80
0.05 2.70
AMEX : Health Care
Prev Close 1.85
Open 1.85
Day Low/High 1.79 / 1.86
52 Wk Low/High 0.56 / 1.75
Volume 457.82K
Avg Volume 1.13M
Exchange AMEX
Shares Outstanding 90.90M
Market Cap 164.52M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

22nd Century Meets With FDA On Modified Risk Tobacco Product Application For World's Lowest Nicotine Tobacco Cigarettes

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company and its wholly-owned subsidiary, Goodrich Tobacco Company, held yesterday...

New International Survey Shows Overwhelming Support For Very Low Nicotine Cigarettes

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company commissioned Harris Poll to conduct an international...

22nd Century And Dent Neurosciences Research Center To Partner On Brain Imaging Clinical Trial

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that it has signed a collaborative research agreement with The Dent...

22nd Century Produces Non-GMO Very Low Nicotine Tobacco

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company's research collaboration with North Carolina State...

22nd Century Group Receives Order For 2.4 Million SPECTRUM® U.S. Government Research Cigarettes

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that its wholly-owned subsidiary, Goodrich Tobacco Company, received...

There Has Been A Dramatic Surge In The Number Of Publications Relating To 22nd Century's Proprietary Very Low Nicotine (VLN) Cigarettes. (Graphic: Business Wire)

22nd Century Group, Inc. (NYSE MKT: XXII) announced today that there has been a dramatic surge in the number of publications relating to the Company's proprietary Very Low Nicotine (VLN) cigarettes.

22nd Century Raises 2017 Revenue Projection To $16Million - Another Record Year

22nd Century Group, Inc. (NYSE MKT: XXII ), a plant biotechnology company, announced today that the Company's wholly-owned subsidiary, NASCO Products, recently entered into substantial new manufacturing agreements for the...

22nd Century Group Files 2017 First Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today the Company's first quarter 2017 financial results and will provide a...

FDA Authorizes Clinical Trial For 22nd Century's BRAND B Low Tar-to-Nicotine Ratio Cigarettes

22nd Century Group, Inc. (NYSE MKT : XXII), announced today that the U.

22nd Century Accepted To Present Proprietary Smoking Cessation Product At BIOCHINA Partnering Forum In Zhuhai, China

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that James Vail, the Company's Director of Business Development,...

22nd Century Will Play Leading Role In Industrial Hemp Industry

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company is building on its newly developed THC-free...

World-Renowned Smoking Cessation Scientist, Dr. Michael Cummings, To Present Keynote Address At 22nd Century Annual Shareholder Meeting

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that K.

New Zealand Study Recommends 22nd Century's VLN Cigarettes As An Effective Tobacco Control Strategy

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the journal Nicotine and Tobacco Research has published a new...

Collect Smokin' Hot Profits From This Marijuana Biotech

Collect Smokin' Hot Profits From This Marijuana Biotech

This innovative biotech offers investors an intriguing play on the medical marijuana business.

22nd Century's "Non- Or Minimally-Addictive" Cigarettes Gaining Support Of Leading Tobacco Scientists Around The World

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that leading scientists published more than 12 new studies involving...

22nd Century Invited To Speak At The Colorado Hemp Expo About The Company's Medical Marijuana Initiatives And Zero-THC Hemp Plants

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction and cannabis research, announced today that representatives of the Company's wholly-owned subsidiary, Botanical Genetics, have been invited to...

22nd Century Produces Zero THC Industrial Hemp At Anandia Labs

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company's research collaboration with strategic partner...

22nd Century Group Issues Annual Letter To Shareholders

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company has issued the following letter to shareholders as...

22nd Century Group Files 2016 Annual Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company filed its 2016 Annual Report on Form 10-K with the...

22nd Century Granted FDA Guidance Meeting For X-22 Smoking Cessation Aid

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, announced today that the Company has been granted a guidance meeting with the Center for Drug...

22nd Century Provided With Written Feedback From FDA On The Company's Modified Risk Tobacco Product Application

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, announced today that the Company has received written feedback from the Center for Tobacco...

Crede Dismisses Claims In Lawsuit Against 22nd Century

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that Crede CG III, Ltd.

22nd Century Prevails Again In Frivolous Crede Lawsuit

22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company prevailed again in the most recent phase of the lawsuit filed by Crede CG...

FDA Provides Positive And Encouraging Feedback For 22nd Century's Very Low Nicotine MRTPA Filings

FDA Provides Positive And Encouraging Feedback For 22nd Century's Very Low Nicotine MRTPA Filings

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, today announced that the U.

22nd Century Group Announces Major Scientific Collaboration With University Of Virginia

22nd Century Group Announces Major Scientific Collaboration With University Of Virginia

22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Company has entered into a sponsored research agreement with the University of...

22nd Century To Present Overview Of Company's Medical Marijuana And Industrial Hemp Initiatives At LD Micro Investor Conference

22nd Century To Present Overview Of Company's Medical Marijuana And Industrial Hemp Initiatives At LD Micro Investor Conference

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction and cannabis research, announced today that the Company will present at the LD Micro Invitational Investor Conference at the Luxe Sunset...

22nd Century Group Files 2016 Third Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group Files 2016 Third Quarter Report And Announces Conference Call To Provide Business Update

22nd Century Group, Inc. (NYSE MKT : XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today the Company's third quarter 2016 financial results and will provide a business update...

Former Santa Fe Natural Tobacco Company Executive Joins 22nd Century

Former Santa Fe Natural Tobacco Company Executive Joins 22nd Century

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction, announced today the hiring of Michael Zercher as the Company's Vice President of Business Development.